AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2942416
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ipratropium powder
Trial: 30875607
Drug: FMS training
RxNorm normalized name: FM-VP4
DrugBank: FM-VP4 (DB05449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMS training (eight weekly 40-min sessions)
Trial: 26343743
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control followed by Cognitive Processing Therapy (CPT)
Trial: 24229753
Drug: olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine plus sertraline
Trial: 19520908
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg twice a day
Trial: 19520908
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 mg twice a day
Trial: 17563395
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 or 30 mg/d)
Trial: 15060689
Drug: Single-dose ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ceftriaxone (50 mg/kg, not exceeding 1 g)
Trial: 15060689
Drug: 10-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day course of amoxicillin-clavulanate (45 mg/kg/day, in 3 divided doses)
Trial: 11574373
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.0625% bupivacaine with fentanyl (3 microg/mL)
Trial: 11574373
Drug: Preservative‐free saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative‐free saline infusion
Trial: 2969860
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA, 50 mg/day orally)
Trial: 2969860
Drug: D‐Trp6 LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐Trp6 LHRH (3 mg i.m. once a month)
Trial: 1969436
Drug: 2% triclosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% triclosan detergent solution
Trial: 138480
Drug: 5-FUDR via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FUDR via hepatic artery infusion (HAI)
Trial: 21649590
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release nicotinic acid 1500 mg
Trial: 17050586
Drug: Azimilide 75
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 75 mg/day
Trial: 9025012
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment for metabolic control
Trial: 8337029
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B control vaccine
Trial: 28958023
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SR-STAIRS with SR-1/4MILE or SR-BLOCKS
Trial: 29076219
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (CaCl2, ZG, CaCl2 + ZG, Saline)
Trial: 24128148
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving methadone‐maintenance treatment for opioid dependence
Trial: 17936278
Drug: Determination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determination of P(ET)CO(2) once daily
Trial: 17936278
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of E(2) or P
Trial: 16310886
Drug: Gemcitabine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1250 mg/m2 on days 1 and 8 + Carboplatin AUC 6 mg/(mLmin) on day 1 (GC)
Trial: 16310886
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m2 weekly + Cisplatin 80 mg/m2 on day 1 (VP)
Trial: 10375806
Drug: Ciclosporin (Cic)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (Cic) 100 mg alone
Trial: 10375806
Drug: Ciclosporin (Cic)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (Cic) 100 mg with Simvastatin (Sim) 10 mg
Trial: 7818264
Drug: Selegiline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline plus L-dopa-carbidopa
Trial: 7818264
Drug: L-dopa-carbidopa alone
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa-carbidopa alone
Trial: 346488
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli H‐10407 (CFA-positive strain) at a dose of 1 X 10(8)
Trial: 346488
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli H‐10407‐P (CFA-negative strain) at a dose of 1 X 10(8)
Trial: 11430963
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg per day
Trial: 26886210
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose e-cigarettes
Trial: 20211530
Drug: Cortisol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (20 mg) administered 1h before retention testing
Trial: 12174030
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg intravenous methylprednisolone in the morning
Trial: 12174030
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg intravenous methylprednisolone in the morning and 16 mg in the evening
Trial: 7843746
Drug: TCV‐116 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV‐116 (4 mg PO daily)
Trial: 7843746
Drug: TCV‐116 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV‐116 (1, 2, or 4 mg PO daily)
Trial: 418637
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of single and double contrast examinations
Trial: 31063679
Drug: Extended antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotics (72 hours of perioperative antibiotics)
Trial: 31063679
Drug: Intraoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative antibiotics only (short antibiotics)
Trial: 25844322
Drug: Levetiracetam 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 62.5 mg BID
Trial: 25844322
Drug: Levetiracetam 125
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 125 mg BID
Trial: 25844322
Drug: Levetiracetam 250
RxNorm normalized name: levetiracetam 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 250 mg BID
Trial: 15385115
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to first-line chemotherapy (CR + PR)
Trial: 15385115
Drug: No response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No response to first-line chemotherapy (SD + PD)
Trial: 12161948
Drug: Biological risk
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological risk assessment
Trial: 29181702
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) therapy
Trial: 1671380
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 mg) with weight loss diet
Trial: 1671380
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 mg) with low sodium/high potassium diet
Trial: 18931095
Drug: Liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.2 mg/day
Trial: 19873688
Drug: Glimepiride 8
RxNorm normalized name: glimepiride 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 8 mg/day
Trial: 18940392
Drug: Higher urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher urinary D‐chiro‐inositol excretion
Trial: 12535037
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block using bupivacaine 0.15% with ketamine 0.5 mg x kg‐1 (n = 30)
Trial: 10395629
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (0.2 percent applied twice daily for six weeks)
Trial: 10395629
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (crossover patients)
Trial: 9332460
Drug: Cisplatin-based combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based combination chemotherapy (vindesine and cisplatin, mitomycin, vindesine and cisplatin, etoposide and cisplatin alternating with vindesine and mitomycin)
Trial: 9332460
Drug: Cisplatin-based combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based combination chemotherapy (EP/VM arm)
Trial: 9332460
Drug: Cisplatin-based combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based combination chemotherapy (MVP and EP/VM arms)
Trial: 8228364
Drug: Large-particle aerosol
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-particle aerosol (LPA) administration of bivalent cold‐adapted influenza A vaccine
Trial: 8228364
Drug: Nose drops
RxNorm normalized name: Nose Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nose drops (ND) administration of bivalent cold‐adapted influenza A vaccine
Trial: 8228364
Drug: Large-particle aerosol
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-particle aerosol (LPA) administration
Trial: 8228364
Drug: Nose drops
RxNorm normalized name: Nose Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nose drops (ND) administration
Trial: 25245629
Drug: Infliximab monotherapy
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab monotherapy
Trial: 22571563
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum ointment applied twice daily for 4 weeks
Trial: 22571563
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment applied twice daily for 4 weeks
Trial: 7650234
Drug: Lidocaine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (200 mg)
Trial: 1672488
Drug: Esmolol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (150 mg)
Trial: 31770051
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection of 9 µg hemagglutinin (HA)/strain
Trial: 31770051
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection of 15 µg HA/strain
Trial: 31770051
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection of 9 µg HA/strain
Trial: 30850406
Drug: Cardiac output-guided
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac output-guided haemodynamic therapy algorithm for intravenous fluid and inotropic drug administration during and in the 6 hours following surgery (n=368)
Trial: 29021285
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (511 IU/d from diet and a cholecalciferol supplement) for 10 weeks
Trial: 19430307
Drug: AIDSVAX B/E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIDSVAX B/E HIV‐1 candidate vaccine
Trial: 17823649
Drug: risperidone 3
RxNorm normalized name: risperidone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone 3 mg daily
Trial: 15592332
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (1.7 mg bergamottin)
Trial: 15592332
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg bergamottin
Trial: 15592332
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg bergamottin
Trial: 15592332
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg bergamottin
Trial: 9765764
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with or without postoperative radiotherapy
Trial: 10470656
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative chemotherapy)
Trial: 7990020
Drug: root planing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: root planing plus a mixture of tetracycline and citric acid‐containing gel (RP + TC‐CAG group)
Trial: 7990020
Drug: tetracycline‐containing gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetracycline‐containing gel alone (TCG group)
Trial: 7990020
Drug: root planing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: root planing plus tetracycline‐containing gel (RP + TCG group)
Trial: 30428836
Drug: Paracetamol (scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (scheduled pain treatment)
Trial: 30428836
Drug: Placebo (corresponding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corresponding placebo treatment)
Trial: 24817695
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins C (1 g) and E (400 IU)
Trial: 20053349
Drug: Oxandrolone 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.03 mg/kg/d
Trial: 20053349
Drug: Oxandrolone 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.06 mg/kg/d
Trial: 20053349
Drug: Oxandrolone 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.03 mg/kg/d or 0.06 mg/kg/d
Trial: 18434455
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin coolant spray
Trial: 8889425
Drug: Ibuprofen arginine
RxNorm normalized name: ibuprofen arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen arginine (400 mg)
Trial: 8889425
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate (5 mg)
Trial: 359108
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate (10 mg)
Trial: 1797888
Drug: Allopurinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (50 mg p.o. q.i.d.)
Trial: 1797888
Drug: DMSO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO (500 mg p.o. q.i.d.)
Trial: 7316037
Drug: Closed suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Closed suction catheter with antibiotic irrigation
Trial: 31794857
Drug: Self-management exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management exercise program (5 sessions) + spa therapy (18 days)
Trial: 31794857
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (spa therapy only, 18 days)
Trial: 25654519
Drug: Tailored exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored exercise program (6-month, twice-a-week)
Trial: 24015719
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (1.4 g·kg body mass⁻¹)
Trial: 24015719
Drug: Carbohydrate (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (1.1 g·kg body mass⁻¹)
Trial: 24015719
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (1.4 g·kg body mass⁻¹)
Trial: 17381533
Drug: dCa 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (ABD-treated group)
Trial: 17381533
Drug: dCa 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (sHPT-treated group)
Trial: 17381533
Drug: dCa 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCa 1.75 mmol/L (ABD-control group)
Trial: 17381533
Drug: dCa 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCa 1.75 mmol/L (sHPT-control group)
Trial: 15446659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of effortful and automatic strategies
Trial: 23116237
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone therapy (o-HT)
Trial: 23116237
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone therapy (t-HT)
Trial: 21606296
Drug: 80-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-kVp protocol with low-dose contrast material (444 mg I/kg body weight) delivered over 15 seconds
Trial: 21606296
Drug: 80-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-kVp protocol with low-dose contrast material
Trial: 21606296
Drug: 120-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120-kVp protocol with standard-dose contrast material (600 mg I/kg) delivered over 30 seconds
Trial: 21606296
Drug: 120-kVp protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120-kVp protocol with standard-dose contrast material
Trial: 19339135
Drug: High counseling
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High counseling combined with bupropion or nicotine patch
Trial: 19339135
Drug: Low counseling
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low counseling combined with bupropion or nicotine patch
Trial: 15389222
Drug: Abciximab and
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab and half-dose reteplase followed by conventional medical therapy (with referral for emergency rescue PTCA allowed in selected cases)
Trial: 15389222
Drug: Abciximab and
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab and half-dose reteplase followed by emergency angioplasty
Trial: 15389222
Drug: Abciximab and
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab and half-dose reteplase
Trial: 11590972
Drug: Typical antipsychotic
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotic treatment
Trial: 9850430
Drug: Phenylpropanolamine 50
RxNorm normalized name: phenylpropanolamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine 50 mg administered at 22.00 h
Trial: 9850430
Drug: Phenylpropanolamine 50
RxNorm normalized name: phenylpropanolamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine 50 mg administered at 10.00 h
Trial: 706
Drug: L-Dopa (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa (900 mg + 225 mg benserazid daily)
Trial: 706
Drug: L-Dopa (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa (600 mg + 150 mg benserazid)
Trial: 706
Drug: L-Dopa (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa (300 mg + 75 mg benserazid)
Trial: 30262209
Drug: EPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPAP therapy
Trial: 20817013
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg HA antigen dose
Trial: 20817013
Drug: Two 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 15 μg HA doses